Biotechnology Tissue Scaffold Regulation In Russia.

1. Introduction

Biotechnology tissue scaffold regulation in Russia concerns the legal control of biological and synthetic materials used to support the growth, attachment, proliferation and regeneration of human tissues.

A tissue scaffold is a three-dimensional biological or synthetic structure that provides a temporary framework for cells to grow and develop into functional tissue. It is an important component of tissue engineering, regenerative medicine, artificial organs, wound healing and advanced biomedical technologies.

Tissue scaffolds may be manufactured using:

Natural polymers such as collagen, gelatin and fibrin.

Synthetic polymers such as polylactic acid (PLA) and polyglycolic acid (PGA).

Decellularised animal or human tissues.

Hydrogel-based biomaterials.

Nanofibres and electrospun materials.

Three-dimensional bioprinting technologies.

Cell-seeded scaffolds for tissue regeneration.

Russia does not have one comprehensive statute exclusively dedicated to tissue scaffolds. Instead, regulation depends on the scaffold's composition, intended medical purpose, biological activity and whether living cells are incorporated.

The principal legal framework includes:

Federal Law No. 323-FZ of 21 November 2011 – Fundamentals of Healthcare Protection.

Federal Law No. 180-FZ of 23 June 2016 – Biomedical Cell Products.

Federal Law No. 61-FZ of 12 April 2010 – Circulation of Medicinal Products.

Government Resolution No. 1684 of 30 November 2024 – State Registration of Medical Devices.

Government Resolution No. 1184 of 3 October 2018 – Licensing of Biomedical Cell Product Manufacturing.

Relevant technical standards, clinical research requirements and sanitary regulations.

The central legal issue is determining whether a tissue scaffold is a medical device, a biomedical cell product, a medicinal product or a human tissue transplantation material.

2. Legal Classification of Tissue Scaffolds in Russia

Classification is particularly important because different categories have different registration, manufacturing, testing and supervision requirements.

Type of scaffoldLikely regulatory classification
Synthetic bone scaffoldMedical device
Acellular collagen scaffoldMedical device, depending on intended use
Hydrogel wound scaffoldMedical device or another regulated product depending on composition and claims
Cell-seeded scaffoldPotential biomedical cell product
Tissue-engineered constructPotential biomedical cell product
Decellularised human tissue for transplantationHuman tissue transplantation framework
Scaffold containing an active medicinal substancePotential medicinal product or combination product

Classification must be made on the actual product and its intended purpose, rather than simply on the manufacturer's terminology.

A. Medical device classification

Article 38 of Federal Law No. 323-FZ provides the general legal framework for medical devices.

A scaffold intended to replace, support or repair damaged tissue may qualify as a medical device when its principal intended medical function falls within that definition.

Examples include:

Bone regeneration scaffolds.

Dental tissue scaffolds.

Cartilage-supporting implants.

Wound-healing matrices.

Surgical tissue-support materials.

Under the medical-device registration framework, safety, quality, technical performance and clinical evidence are important regulatory considerations.

The current registration rules are contained in Government Resolution No. 1684 of 30 November 2024.

roszdravnadzor.gov.ru+1

 

B. Biomedical cell product classification

Federal Law No. 180-FZ is particularly important when living cells are incorporated into tissue scaffolds.

A biomedical cell product can involve a cell line combined with auxiliary substances, or a cell line combined with auxiliary substances and registered medicinal products or medical devices.

Consequently, a scaffold containing living cells may fall within this legislation if it satisfies the statutory definition.

However, not every cell-containing tissue product automatically qualifies. Human tissue transplantation and other expressly excluded categories must be distinguished from biomedical cell products.

cis-legislation.com+1

 

3. Federal Law No. 323-FZ: Healthcare Protection

Federal Law No. 323-FZ establishes the general legal principles governing healthcare, patient rights, medical intervention and medical-device circulation.

Its importance for tissue scaffold technology can be explained through four major areas.

First, patient safety: Tissue scaffold implantation must comply with applicable medical safety requirements.

Second, medical-device registration: Products classified as medical devices generally require state registration before lawful circulation in Russia.

Third, medical intervention: Implantation procedures must comply with applicable informed-consent and medical-care requirements.

Fourth, professional responsibility: Healthcare organisations and medical professionals may incur liability where improper selection, implantation or monitoring causes patient injury.

Article 38 is especially significant because unregistered medical devices generally cannot lawfully circulate in Russia.

roszdravnadzor.gov.ru+1

 

4. Federal Law No. 180-FZ: Biomedical Cell Products

Federal Law No. 180-FZ, adopted on 23 June 2016, provides a specialised framework for biomedical cell products.

It is relevant to tissue engineering where scaffolds function as carriers or supporting structures for therapeutic cells.

Important regulatory requirements

A. State registration

Article 8 establishes state-registration requirements for biomedical cell products.

The legislation regulates their production, sale, use, storage, transportation, export and destruction.

Registration involves:

Product-quality examination.

Examination of the relevant documentation.

Evaluation of effectiveness.

Assessment of expected benefits and possible risks.

Ethical examination.

Clinical investigations.

The legislation provides a registration period of up to 150 working days in the ordinary statutory procedure, subject to the circumstances specified by the law.

Consultant Plus+1

 

B. Manufacturing authorisation

Manufacturers of biomedical cell products must comply with the applicable licensing requirements.

Government Resolution No. 1184 of 3 October 2018 establishes the licensing framework for this activity.

C. Good manufacturing and handling practices

The applicable good-practice rules require appropriate production systems, quality control, documentation and handling procedures.

Ministry of Health Order No. 512n of 8 August 2018 is an important instrument governing proper practices for handling biomedical cell products.

cis-legislation.com+1

 

5. Manufacturing and Quality-Control Requirements

Tissue scaffold manufacturers must establish a quality-management system appropriate to the product's classification and risk.

The following requirements are particularly important.

A. Raw material control

Manufacturers should maintain records identifying:

The origin of collagen and other biomaterials.

The source of animal or human tissues.

The purity of synthetic polymers.

The chemical composition of hydrogels.

The presence of residual processing chemicals.

The biological safety of raw materials.

For animal-derived scaffolds, traceability and controls against biological contamination are especially important.

B. Sterilisation and contamination control

Scaffolds intended for implantation must undergo appropriate validation of sterilisation and microbiological safety.

Relevant risks include:

Bacterial contamination.

Viral contamination.

Endotoxin contamination.

Residual sterilisation chemicals.

Structural damage during sterilisation.

Loss of mechanical strength.

C. Biocompatibility testing

A manufacturer should assess whether the scaffold produces harmful reactions when exposed to biological tissues.

Important testing considerations include:

Cytotoxicity.

Sensitisation.

Irritation.

Implantation response.

Degradation products.

Inflammatory reactions.

Mechanical stability.

Biological compatibility.

The ISO 10993 series of standards provides an important international technical framework for evaluating the biological safety of medical devices.

D. Scaffold degradation

Biodegradable scaffolds require additional evaluation.

For example, a bone-regeneration scaffold should maintain sufficient mechanical support while the patient's natural bone tissue develops.

If degradation occurs too quickly, structural failure may result.

If degradation is excessively slow, the remaining material may interfere with tissue regeneration.

Manufacturers should therefore demonstrate that degradation characteristics are appropriate for the intended medical application.

6. Clinical Investigation and Evidence Requirements

Clinical evidence is particularly important for implantable tissue scaffolds.

The manufacturer must establish that the product performs its intended function without creating unacceptable risks.

Clinical evaluation may consider:

Tissue regeneration rates.

Implant survival.

Inflammatory responses.

Infection rates.

Implant rejection.

Mechanical failure.

Long-term degradation.

Revision surgery.

Patient-reported outcomes.

For biomedical cell products, Federal Law No. 180-FZ specifically establishes clinical investigation and ethical examination requirements.

For medical devices, the applicable requirements under Federal Law No. 323-FZ and Government Resolution No. 1684 must be considered.

A manufacturer cannot assume that laboratory success or animal experiments automatically establish clinical safety in humans.

7. Importation and Commercialisation of Tissue Scaffolds

Russia regulates the circulation of medical devices through a state-registration system.

Foreign manufacturers intending to commercialise tissue scaffolds in Russia must first determine the applicable product category.

Their compliance responsibilities may include:

Establishing the correct regulatory classification.

Preparing technical documentation.

Providing appropriate safety and performance evidence.

Obtaining the required registration.

Complying with applicable conformity and quality requirements.

Maintaining post-market safety information.

Complying with applicable import and customs rules.

Where a product is classified as a biomedical cell product, the additional requirements of Federal Law No. 180-FZ become relevant.

For cell-containing products, foreign manufacturers must also carefully assess whether the product falls within the Russian biomedical cell product regime or another applicable medicinal-product framework.

8. Intellectual Property Protection and Tissue Scaffold Innovation

Tissue scaffold technology frequently involves valuable intellectual property.

Russian intellectual property law provides several mechanisms for protecting innovation.

A. Patent protection

Part IV of the Civil Code of the Russian Federation governs intellectual property rights.

Patent protection may be available for qualifying inventions involving:

Novel scaffold compositions.

Biomaterial manufacturing processes.

Three-dimensional scaffold architectures.

Biodegradable polymer combinations.

Tissue regeneration technologies.

Novel methods of producing scaffold structures.

An invention must satisfy the applicable patentability requirements, including novelty, inventive step and industrial applicability.

B. Trade secrets

Manufacturers may protect confidential technical information through trade-secret arrangements.

Examples include:

Proprietary collagen extraction methods.

Scaffold fabrication parameters.

Special sterilisation processes.

Biomaterial purification techniques.

Manufacturing specifications.

C. Patent ownership disputes

Disputes may arise between universities, research institutions, scientists and biotechnology companies concerning ownership of scaffold inventions.

Employment agreements, research agreements, technology-transfer contracts and applicable provisions of the Civil Code are relevant to resolving these disputes.

9. Liability for Tissue Scaffold Failures

Tissue scaffold failures can create civil, administrative and, in serious circumstances, criminal liability.

A. Manufacturer liability

A manufacturer may face liability where:

The scaffold contains harmful substances.

Manufacturing defects cause implantation failure.

The product is improperly sterilised.

Technical documentation contains misleading information.

The product fails to satisfy applicable safety requirements.

B. Medical institution liability

A hospital may face liability for negligent implantation, inadequate patient assessment or failure to monitor complications.

C. Medical professional liability

A medical professional may incur liability where improper surgical techniques, incorrect scaffold selection or inadequate postoperative management causes harm.

D. Product-related compensation

The Russian Civil Code, including its provisions on compensation for harm caused by defective goods and services, is relevant to tissue scaffold injury claims.

The Consumer Protection Law No. 2300-1 of 7 February 1992 may also apply where the relevant patient-provider or product-supply relationship falls within its scope.

10. Important Russian Case Laws Relating to Tissue Scaffold Regulation

Directly reported Russian Supreme Court decisions specifically interpreting tissue scaffold technology are limited. Nevertheless, several important judicial decisions concerning collagen matrices, biological implants and medical-device registration provide useful legal guidance.

The following cases are particularly relevant.

Case 1. CardioPlant LLC v. Financial Treasury Authority of Penza Region

Directly relevant tissue-engineering dispute

Court: Arbitration Court of the Penza Region.

Date: 17 June 2024.

Case No.: А49-9896/2023.

Facts:

CardioPlant LLC was involved in the development and commercialisation of biological xenogeneic implants for replacing damaged human tissues.

Its project included several tissue-engineering products, such as:

3D collagen matrix FibroMATRIX.

Osteoplastic biological matrices.

Collagen membranes for tissue regeneration.

Biological implants used in neurosurgery.

Xenogeneic tissue-based medical products.

A dispute arose concerning the utilisation of federal subsidies and whether the company had achieved the required project milestones, particularly the registration and commercialisation of certain medical devices.

Legal issues:

Whether the relevant research and development expenses were connected with the approved innovation project.

Whether particular biological implants had obtained the required registration.

Whether different product names and variants represented the same registered medical device.

Whether the company had fulfilled its subsidy obligations.

Judicial significance:

The dispute demonstrates that tissue-engineering manufacturers must maintain clear documentation connecting product development, clinical evaluation, technical specifications and registration.

It also demonstrates the importance of distinguishing between individual product variants and the products covered by a registration certificate.

Relevance to tissue scaffold regulation:

This is particularly important for collagen-based scaffolds and biological matrices because changes in composition, manufacturing or product variants may have regulatory consequences.

Source:

Sudact+1

 

Case 2. Eleventh Arbitration Court of Appeal – CardioPlant Dispute

Court: Eleventh Arbitration Court of Appeal.

Date: 4 September 2024.

Case No.: 11АП-11429/24.

Underlying case: А49-9896/2023.

Facts:

The appeal concerned the same innovation project involving biological xenogeneic implants.

The evidence included documentation relating to the development and clinical evaluation of collagen matrices, biological implants and tissue-repair materials.

Legal issues:

The proceedings addressed the relationship between the project's contractual obligations, product registration, technical documentation and government subsidy requirements.

Significance:

This case illustrates the importance of maintaining consistency between:

Product descriptions.

Technical specifications.

Registration certificates.

Clinical testing documentation.

Commercialisation milestones.

For scaffold manufacturers, a product's technical identity and regulatory documentation should be consistent throughout its development and commercialisation.

Source:

ГАРАНТ+1

 

Case 3. Arbitration Court of the Volga District – CardioPlant Dispute

Court: Arbitration Court of the Volga District.

Date: 20 December 2024.

Case No.: Ф06-10121/24.

Underlying case: А49-9896/2023.

Facts:

The litigation concerned government funding and the development of implantable biological medical devices.

The products included animal-origin bone matrices, composite bone implants, collagen-based dental regeneration membranes and biological dural substitutes.

Legal issues:

The court proceedings involved the classification and identification of medical products and the question of whether the company's regulatory and project documentation demonstrated compliance with the relevant obligations.

Significance:

The dispute is important because it demonstrates that a biological implant's classification and product identity must be supported by technical and registration documentation.

For tissue scaffold businesses, the practical lesson is that a manufacturer should not assume that a product is covered by an existing registration merely because its commercial name or general function resembles another registered product.

Source:

ГАРАНТ+1

 

Important case-law qualification: These are proceedings within the same underlying litigation, not three independent judicial precedents. They concern biological implants and collagen matrices rather than a standalone legal challenge to a tissue scaffold statute. Their relevance is therefore principally by analogy.

11. Regulatory Authorities Responsible for Tissue Scaffold Oversight

Several Russian authorities have responsibilities relevant to tissue scaffold development and commercialisation.

AuthorityRegulatory responsibility
Ministry of Health of RussiaHealthcare policy and biomedical cell product regulation
RoszdravnadzorMedical-device registration and healthcare supervision
RospotrebnadzorSanitary and epidemiological requirements
Federal Accreditation Service (Rosakkreditatsiya)Accreditation of testing and conformity-assessment bodies
Federal Service for Intellectual Property (Rospatent)Patent and intellectual property protection

Roszdravnadzor is particularly important for medical-device registration and licensing of biomedical cell product manufacturing.

16reg.roszdravnadzor.ru+2

 

12. Major Legal Challenges in Russian Tissue Scaffold Regulation

Russia faces several important regulatory challenges in tissue engineering.

1. Classification uncertainty: A scaffold may be classified differently depending on whether it is acellular, cell-containing, medicinally active or derived from human tissue.

2. Xenogeneic material safety: Animal-derived scaffolds require appropriate controls concerning infectious agents, immunogenicity and biological contamination.

3. Three-dimensional bioprinting: Existing product classifications must be applied to increasingly complex products involving living cells and printed biomaterials.

4. Long-term clinical monitoring: Implantable scaffolds may degrade over several years, creating difficulties in evaluating long-term safety.

5. Cross-border regulatory recognition: Foreign scaffold manufacturers may encounter differences between Russian registration requirements and international regulatory systems.

6. Intellectual property disputes: Ownership of scaffold compositions and manufacturing processes can become complicated when universities and commercial manufacturers collaborate.

7. Product liability: Determining whether an implant failure resulted from a defective scaffold, surgical negligence or patient-specific biological factors can be difficult.

13. Recommendations for Strengthening Tissue Scaffold Governance in Russia

The Russian regulatory framework could benefit from several improvements:

Establishing clearer classification guidance for acellular and cell-containing scaffolds.

Developing specialised technical standards for biodegradable tissue matrices.

Strengthening long-term post-market surveillance of implantable biomaterials.

Establishing more detailed testing protocols for xenogeneic scaffold materials.

Improving regulatory guidance for 3D-bioprinted tissue constructs.

Developing transparent procedures for assessing scaffold degradation and tissue integration.

Strengthening cooperation between research institutions, hospitals and manufacturers.

Improving the legal framework for compensation in cases of tissue scaffold-related injuries.

14. Conclusion

Biotechnology tissue scaffold regulation in Russia operates through a combination of medical-device legislation, biomedical cell product legislation, medicinal-product regulation and human tissue transplantation rules.

Federal Law No. 323-FZ provides the general healthcare and medical-device framework, while Federal Law No. 180-FZ becomes particularly important when a tissue scaffold forms part of a regulated biomedical cell product.

Government Resolution No. 1684 of 30 November 2024 establishes the current general medical-device registration rules.

The CardioPlant litigation, particularly Case No. А49-9896/2023 and its appellate and cassation proceedings, provides valuable judicial material concerning collagen matrices, biological implants, product registration and regulatory documentation.

Ultimately, the central legal objective is to ensure that tissue scaffolds are scientifically reliable, properly classified, safely manufactured, appropriately registered and clinically suitable before being introduced into medical practice.

15. Important Legal References and Research Sources

Legal instrumentSubject
Federal Law No. 323-FZ (2011)Healthcare protection and medical devices
Federal Law No. 180-FZ (2016)Biomedical cell products
Federal Law No. 61-FZ (2010)Medicinal products
Government Resolution No. 1684 (2024)Medical-device registration
Government Resolution No. 1184 (2018)Biomedical cell product manufacturing licences
Ministry of Health Order No. 512n (2018)Good practices for biomedical cell products
Civil Code of the Russian FederationIntellectual property and civil liability

Further reading:

Federal Law No. 180-FZ – Biomedical Cell Products.

Roszdravnadzor – Medical Device Registration.

Almost 40 Years of Tissue Engineering in Russia: Where Are We Now?.

CardioPlant – Arbitration Case No. А49-9896/2023.

Arbitration Court of the Volga District – 20 December 2024.

Academic research note: The analysis distinguishes binding legislation from judicial decisions and analogous cases. It does not suggest that Russia has a separate comprehensive Tissue Scaffold Act or that the CardioPlant judgments directly establish a dedicated tissue-scaffold doctrine.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT